31578 Federal Register / Vol. 65, No. 97 / Thursday, May 18, 2000 / Notices

single oligodeoxynucleotide containing

multiple different motifs. The

oligodeoxynucleotides of the current

invention have the capacity to stimulate

humoral, cell-mediated immune

responses or both humoral and cellmediated immune responses, depending

on the motifs utilized. The

oligodeoxynucleotides of the present

invention have uses including, but not

limited to, treating allergies infectious

diseases, cancer, and autoimmune

disorders; furthermore, the

obligodeoxynucleotides of the present

invention have utility as vaccine

adjutants for conventional and DNA

vaccines, and as anti-sense therapeutics.

A Novel Neuropeptide Potentially

Involved in Pain Regulation, Blood

Pressure Control, and Other

Physiological Functions

Dr. Ted. Usdin (NIMH)

DHHS Reference No. E–123–99/0 filed

15 Jun 1999

Licensing Contact: Norbert Pontzer; 301/

496–7736 ext. 284; e-mail:

np59n@nih.gov

A 39 amino acid peptide which

activates the newly discovered

parathyroid 2 (PTH2) receptor has been

isolated, sequenced and cloned. The

PTH2 receptor is a member of the

secretin receptor family which includes

receptors for secretin, vasoactive

intestinal polypeptide, calcitonin,

glucagon, gastric inhibitory polypeptide

and CRF. Immunohistochemical

mapping of the PTH2 receptor shows a

distribution of PTH2 receptor in:

endocrine tissue including pancreatic

islet somatostatin cells; thyroid

parafollincular cells and peptide

secreting cells in the intestine; heart

muscle, and nervous tissue including

areas of the hypothalamus involve din

pituitary regulation and the somatic and

visceral primary sensory neuron

terminals in the dorsal horn of the

spinal column. This distribution

suggests that the ligand or an antagonist

may be used to treat pain, high blood

pressure, diabetes, GI disturbances,

psychiatric disease and other

pathologies.

Novel Disulfide Conjugated Cell Toxins

and Methods of Making and Using

Them

David Fitzgerald, Michael J. Iadarola

(NCI)

DHHS Reference No. E–301–99/0 filed

22 Oct 1999

Licensing Contact: Marlene Shinn; 301/

496–7056 ext. 285; e-mail:

ms482m@nih.gov

Efforts to find more effective

treatments of chronic pain with few

unwanted side effects or which do not

dampen acutely painful potentially

dangerous stimuli remains a continuing

challenge. Current analgesic therapies

often fall short of therapeutic goals and

typically have unacceptable side effects.

Thus the discovery of a more efficacious

and safe means to control chronic pain

is unpredictable and therapeutically

advantageous.

The NIH announces a new technology

which is an effective treatment for pain

control directed at the local ablation of

NK–1 receptor expressing cells. The

NK–1 receptor is found on a variety of

cell types, the predominant expressing

cells being pain-mediating neurons.

Other cell types include brain cells and

neostriatum cells through the axon

collaterals of spiny projection neurons

to name a few. This technology is the

discovery of a novel conjugate generated

between TNB–derivatized Substance P

(SP) and a truncated version of

Pseudomonas exotoxin, termed PE35.

When administered to NK–1 receptor

expressing cells, SP–PE35 induced cell

death, while cells that expressed NK–2

and NK–3 receptors remained

unaffected. This toxin allows for the

killing of a specific category of cell

types and is an effective means of

treating a variety of conditions, in

particular chronic pain or tumors that

express NK–1 receptors. The toxin can

be placed in a pharmaceutically

acceptable excipient and can be

combined with any method of

procedure currently being used

clinically, making it a versatile and

superior form of treatment.

Dated: April 25, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, National Institutes of Health.

[FR Doc. 00–12546 Filed 5–17–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by

contacting Vasant Gandhi, J.D., Ph.D., at

the Office of Technology Transfer,

National Institutes of Health, 6011

Executive Boulevard, Suite 325,

Rockville, Maryland 20852–3804;

telephone: 301/496–7056 ext. 224; fax:

301/402–0220; e-mail: vg48q@nih.gov.

A signed Confidential Disclosure

Agreement will be required to receive

copies of the patent applications.

Peptides That Inhibit the Binding of

Human Monocyte Chemoattractant

Protein-1 (MCP–1) to Its Receptor CCR2

Teizo Yoshimura (NCI)

DHHS Reference No. E–235–99/0 filed

30 Nov 1999

MCP–1 is a chemoattractant protein

and is a member of a family of

proinflammatory cytokines called

chemokines. Chemokines are of interest

because of their ability to attract and

activate specific leukocyte subsets to the

exclusion of others. In particular, MCP–

1 is capable of attracting monocytes but

not neutrophils. The inventors isolated

peptides with an antibody (E11) that

immunoreacts with MCP–1. One such

peptide may be useful in blocking the

interaction of MCP–1 and its receptor

CCR2 which may disrupt the formation

and/or progression of a variety of

disease states. MCP–1 has been detected

in lesions of atherosclerosis, rheumatoid

arthritis, pulmonary fibrosis and tumors

such as malignant fibrous histiocytoma,

malignant glioma, meningioma or

melanoma.

Inhibition of ABC Transporters by

Transmembrane Domain Analogs

Nadya Tarasova, Michael M Gottesman,

Christine Hrycyna,

Christopher J Michejda (NCI)

DHHS Reference No. E–019–00/0 filed

18 Nov 1999

ABC transporters contain multiple

transmembrane domains and are

involved in the translocation of a variety

of substrates across cell membranes.

Upregulation of these transporters

contributes to multiple drug resistance

in cancer chemotherapy. The inventors

have found that the P-gp (P-glycoprotein

or Multiple Drug Resistance Protein-1)

can be inhibited by properly substituted

peptides corresponding to one of the

transmembrane domains. Such

inhibition can be used to enhance the

activity of cancer chemotherapy in

resistant tumors.

Federal Register / Vol. 65, No. 97 / Thursday, May 18, 2000 / Notices 31579

Assay for the Detection of a Variety of

Tumors in Biological Specimens

Larry W. Fisher, Neal S. Fedarko,

Marian F. Young (NICHD)

DHHS Reference No. E–173–98/0 filed

09 Apr 1999

The inventors have developed

methods and reagents for the detection

of bone sialoprotein (BSP) in biological

samples. The technology relates to the

disruption of a serum complex that

masks the majority of BSP from

established detection systems.

Furthermore, there is evidence that

there may be a more acidic form of BSP

secreted not by normal bone, but only

by tumors. Detection of BSP in serum

may be a good marker of various bone

diseases and a variety of cancers

including breast, prostate, lung, and

thyroid.

Dated: April 25, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 00–12547 Filed 5–17–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Center for Complementary &

Alternative Medicine; Notice of Closed

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Center for

Complementary and Alternative Medicine

Special Emphasis Panel.

Date: June 5–7, 2000.

Time: 8:30 am to 1:00 pm.

Agenda: To review and evaluate grant

applications.

Place: 6001 Executive Blvd., Room A1/A2,

Rockville, MD 20852.

Contact Person: Eugene G. Hayunga, PhD,

Scientific Review Administrator, National

Institutes of Health, NCCAM, Building 31,

Room 5B50, 9000 Rockville Pike, Bethesda,

MD 20892, 301–594–2014,

hayungae@od.nih.gov.

Dated: May 4, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–12544 Filed 5–17–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Closed meetings.

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Heart, Lung,

and Blood Institute Special Emphasis Panel.

Date: June 14, 2000.

Time: 8:30 am to 5 pm.

Agenda: To review and evaluate grant

applications.

Place: Holiday Inn Chevy Chase, 5520

Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: Louise P. Corman, PhD,

Scientific Review Administrator, Review

Branch, NIH, NHLBI, Rockledge Building II,

6701 Rockledge Drive, Suite 7180, Bethesda,

MD 20892–7924, (301) 435–0270.

Name of Committee: National Heart, Lung,

and Blood Institute Special Emphasis Panel,

Clinical Trials Special Emphasis Panel.

Date: June 27, 2000.

Time: 8 am to 1 pm.

Agenda: To review and evaluate grant

applications.

Place: Hyatt Regency Bethesda, One

Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Joyce A. Hunter, National

Heart, Lung, and Blood Inst., NIH, Rockledge

Center, II, 6701 Rockledge Drive, Suite 7194,

Bethesda, MD 20892–7924, 301/435–0288.

Name of Committee: National Heart, Lung,

and Blood Institute Special Emphasis Panel.

Date: July 13, 2000.

Time: 9 am to 3:30 pm.

Agenda: To review and evaluate grant

applications.

Place: Hilton National Airport Hotel, 2399

Jefferson Davis Highway, Arlington, VA

22202.

Contact Person: Louise P. Corman, PhD,

Scientific Review Administrator, Review

Branch, NIH, NHLBI, Rockledge Building II,

6701 Rockledge Drive, Suite 7180, Bethesda,

MD 20892–7924, (301) 435–0270.

Name of Committee: National Heart, Lung,

and Blood Institute Special Emphasis Panel.

Date: July 14, 2000.

Time: 9 am to 12:30 pm.

Agenda: To review and evaluate grant

applications.

Place: Washington National Airport Hilton,

2399 Jefferson Davis Highway, Arlington, VA

22202.

Contact Person: Louise P. Corman, PhD,

Scientific Review, Administrator, Review

Branch, NIH, NHLBI, Rockledge Building II,

6701 Rockledge Drive, Suite 7180, Bethesda,

MD 20892–7924, (301) 435–0270.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.233, National Center for

Sleep Disorders Research; 93.837, Heart and

Vascular Diseases Research; 93.838, Lung

Diseases Research; 93.839, Blood Diseases

and Resources Research, National Institutes

of Health, HHS)

Dated: May 10, 2000.

LaVerne Y. Stringfield,

Director, Office of Fedeal Advisory Committee

Policy.

[FR Doc. 00–12543 Filed 5–17–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse

and Alcoholism; Notice of Closed

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute on

Alcohol Abuse and Alcoholism Special

Emphasis Panel.

Date: June 15, 2000.

Time: 4 p.m. to 5 p.m.

Agenda: To review and evaluate grant

applications.

Place: Holiday Inn, Bethesda, MD 20814.

Contact Person: Elsie D. Taylor, Scientific

Review Administrator, Extramural Project

Review Branch, National Institute of Alcohol